Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
AssigneesMedarex, Inc., Amgen Inc.
InventorsAndrew A. Welcher, Hilary T. Chute, Yue-Sheng Luke Li, Haichun Huang
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
Claims21
1-30. (canceled)
A method for treating a patient having systemic lupus erythematosus comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
A method for treating a patient having an inflammatory bowel disease comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
A method for treating a patient having psoriasis comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
Dependencies are inferred from the claim text.